$12.7M Blows in for Wind Power Holdings, Epizyme Forges Alliance with GlaxoSmithKline, & Many More Boston-Area Deals
Dealmaking activity in New England’s tech and life sciences sectors continued at a blizzardy pace this week. Hold on to your hat…
—Marlborough, MA-based biofuels developer Qteros raised $22 million from new and existing investors in the first tranche of a Series C financing.
—IT services provider MindShift Technologies of Waltham, MA, acquired Alpheon, a Morrisville, NC-based IT firm focusing on healthcare clients.
—Somerville, MA-based XL Hybrids, which converts commercial vehicles into hybrids, took in $2 million from undisclosed investors and forged an alliance with U.K.-based retrofit kin maker Ashwoods Automotive.
—Waltham-based On-Q-ity inked a deal with Laboratory Corporation of America (NYSE:LH) to commercialize On-Q-ity’s technology for detecting tumor cells circulating in the blood.
—Civitas, a Chelsea, MA-based spinout of Alkermes (NASDAQ:ALKS) focusing on inhaled drug-delivery technology, raised $20 million in a Series A round led by Longitude Capital and Canaan Partners.
—Cambridge-based Epizyme, a developer of drugs based on the emerging science of epigenetics, partnered with pharmaceutical giant GlaxoSmithKline in a deal worth $20 million upfront and up to $630 million more in milestones fees.
—Barre, VT-based Wind Power Holdings, the parent company of wind turbine developer Northern Power Systems, raised $12.7 million in equity-based funding from 33 investors, according to an SEC filing.
—Boston-based educational software maker Jenzabar acquired the assets of Allurent, the e-commerce firm reported to be defunct last month, and will invest a “seven-figure sum” in Allurent over the next 12 months, according to Jenzabar CEO Robert Maginn.
—Antibiotic developer Rib-X Pharmaceuticals of New Haven, CT, raised $20 million in a financing round led by Warburg Pincus.
—A number of other startups scored venture dollars as well: Concord, MA-based KnowledgeVision Systems ($2 million from GrandBanks Capital and others); Cambridge, MA-based Labtiva ($2 million); Newton, MA-based Life Image ($12M from Cardinal Partners and Galen Partners); Waltham, MA-based EyeGate Pharmaceuticals ($5.9 million); Acton, MA-based Neuroptix ($4.6 million); Waltham-based DynaTrace Software ($4 million); Southbury, CT-based Doctors Research Group ($7.7 million); and Cambridge-based Dekkun ($9.9 million).